NATURAL CAPSULES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 135 | 172 | 155 | 169 | 187 |
| EBITDA (ex other income) | 25 | 34 | 20 | 18 | (2) |
| margin % | 18.8 | 19.8 | 12.8 | 10.4 | (0.8) |
| Owners' profit | 0 | 0 | 6 | 1 | (17) |
| EPS, as reported (₹) | 19.56 | 18.87 | 6.23 | 0.22 | (23.84) |
| ROE % · ROCE % | 16.8 · 18.1 | 11.9 · 12.5 | 2.4 · 4.4 | 0.2 · 2.9 | (10.5) · (5.8) |
| Debt / equity (x) | 0.61 | 0.66 | 0.48 | 0.40 | 0.49 |
| Cash from operations | 1 | 16 | (8) | 27 | 11 |
| Capex | (44) | (106) | (71) | (45) | (12) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 44 | 45 | 45 | 46 | 38 | 58 | 49 |
| Profit before tax | 1 | 1 | 1 | (6) | (8) | (9) | (5) | (6) |
| Net profit | (1) | 0 | 1 | (6) | (7) | (7) | (5) | (6) |
| EPS (₹) | (0.60) | 0.10 | 0.13 | (5.40) | (6.76) | (6.88) | (4.82) | (5.55) |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Capsules | 130 | 69.2 |
| API | 12 | 6.7 |
| a)Capsules | 44 | 23.6 |
| b)API | 1 | 0.5 |
| Total, before eliminations | 187 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · EGM approves preferential allotment of shares and convertible warrants | board shareholder meetings | medium | — | — |
| 9 Sept 2026 · EGM held; preferential issue of shares and warrants considered | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Corrigendum to EGM Notice published; preferential issue pricing revised | compliance | minimal | — | — |
| 2 Sept 2026 · Corrigendum to EGM Notice - Revised Preferential Issue Terms | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Board approves revised preferential issue terms to promoter at 178 rupees | fund raising | high | — | — |
| 1 Sept 2026 · Board meeting on Sep 2 to revise preferential issue price and warrants | fund raising | low | — | — |
| 19 Aug 2026 · Newspaper publication copy submitted to exchange | compliance | minimal | — | — |
| 19 Aug 2026 · Notice of EGM published in newspapers | compliance | minimal | — | — |
| 18 Aug 2026 · Notice of EGM to be held on September 9, 2026 via video conferencing | compliance | minimal | — | — |
| 18 Aug 2026 · Record date set at September 2, 2026 for upcoming EGM on September 9, 2026 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| DIVI S LABORATORIES LTD |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 0.8 | 3.3 | 13 of 163 | 92% |
| ROCE | (9.6) | 10.8 | 167 of 183 | 9% |
| ROE | (10.5) | 10.4 | 160 of 171 | 7% |
| Debt / Equity | 0.5 | 0.1 | 141 of 171 | 18% |
| EBITDA margin | 7.1 | 17.5 | 134 of 165 | 19% |
| Revenue growth | 7.8 | 16.3 | 102 of 161 | 37% |
| Profit growth | (2.9) | 30.9 | 108 of 158 | 32% |
| Market cap | 196 | 839 | 116 of 182 | 37% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
